Navigation Links
Reportlinker Adds Global Biosimilars (Follow-on biologics) Market: An Analysis

NEW YORK, Nov. 18, 2010 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Global Biosimilars (Follow-on biologics) Market: An Analysis

Biosimilars or FOBs (Follow-on biologics) refer to generic versions of patented branded biological drugs, developed subsequent to the patent expiry of brand name products. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. In 2009, biosimilar recombinant non glycosylated protein products formed the largest market segment since blockbuster biopharmaceutical drug such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications.

Overburdened due to rising healthcare costs, ageing population, expensive drugs and pharmaceutical expenditure, biosimilar market is getting boost from increasing user acceptance and emerging Indian and Chinese markets. The major challenge for the biosimilar market is risk involved with the high investment and possible failure of the drug during development stages. However, opportunities for biosimilar market is immense, as biologics are going to be off patent by 2015 and an anticipated approval pathway in U.S. will open up potentially largest market. The growth potential of the biosimilars market is expected to be strong, with patents for a number of second-generation therapeutic proteins (Enbrel, Remicade, Herceptin, etc.) slated for expiry between 2013 and 2019. The global biosimilars market is highly fragmented with the presence of some leading players such as Biocon, Dr Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt.

The report titled "Global Biosimilars (Follow-on biologics) Market: An Analysis" covers the overview, market size and segmentation of the biosimilars market. The various drivers and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.

1. Global Biopharmaceutical Market

2. Global Biosimilars Market

2.1 Overview

2.2 Market Size

2.3 Geographical Segmentation

2.4 Currently Marketed Biosimilars

2.4.1 Erythropoietin

2.4.2 Human Growth Hormone

2.4.3 Filgrastim

3. Market Drivers

3.1 Rising Healthcare Costs

3.2 Large Number of Blockbuster Biologics Slated for Patent Expiry

3.3 Leading Generics Players Spearheading Development

3.4 Rise in Ageing Population

3.5 Cost Effective Option for Pharmaceutical Companies

4. Market Constraints

4.1 Regulatory Restrictions and Hurdles

4.2 High Development Costs 24

4.3 Manufacturing Complexities

5. Opportunities

5.1 Burgeoning Indian and Chinese Market

5.2 Monoclonal Antibodies- Fastest Growing segment

6. Market Outlook

7. Major Players

7.1 Teva Pharmaceuticals Industries Ltd.

7.1.1 Business Description

7.1.2 Business Strategies

7.2 Biocon

7.2.1 Business Description

7.2.2 Business Strategies

7.3 Hospira Inc.

7.3.1 Business Description

7.3.2 Business Strategies

Charts and FiguresBiopharmaceutical Value Chain

Global Biopharmaceutical Market (2004-2009)

Global Biopharmaceutical Market by Product (2009)

Categories of Biosimilars Market

Biosimilars Development Process

Difference between Small Molecule Generics and Biosimilars

Global Biosimilar Market Revenue (2008-2014F)

Global Biosimilars Market by Product (2009)

Global Market Potential for Biosimilars in Different Categories (2009)

Major Blockbuster biologics whose patents will expire from 2012- 2019

Marketed Biosimilars by Product Group

Total Healthcare Expenditure Per Capita in Selected Developed Countries (2008)

Real Annual Growth in per Capita Health Spending (%): 2000-2008

Potential Market Potential for Biosimilars

Leading Players in Biosimilars market and Products in Pipeline

Ageing Population Worldwide (age>65) 2005-2015F

Cost Comparison of Biosimilars and Innovator Biologics

Biosimilar Approval in EU

Indian Biosimilars Market Revenue (2008-2012F)

India's Biosimilar Market Breakdown (2009)

Potential Global Market for Biosimilars (2008-2015)

Number of Biologics Scheduled to Go-off Patent (2008-2015)

Annual Revenues of Teva Pharmaceuticals (2005-2009)

Annual Revenues of Biocon (FY 06-FY 10)

Annual Revenues of Hospira Inc. (2009)

To order this report:Biotechnology Industry: Global Biosimilars (Follow-on biologics) Market: An Analysis

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805) 652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

2. Reportlinker Adds Global HPLC Systems & Accessories Industry
3. Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry
4. Reportlinker Adds Global Freeze Drying Equipment Industry
5. Reportlinker Adds Global Surgical Incision Closures Industry
6. Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
7. Reportlinker Adds Global Uro-Gynecological Surgical Devices Industry
8. Reportlinker Adds Global Sterilization Systems & Equipment Industry
9. Reportlinker Adds Global Breast Pumps Industry
10. Reportlinker Adds Healthcare Reform: 2010 Medical Device Industry Perceptions Survey
11. Reportlinker Adds Global Nutraceuticals Industry
Post Your Comments:
(Date:10/12/2015)... COSTA MESA, Calif. , Oct. 12, 2015 ... reaffirmed the accreditation of Harbor Compounding Pharmacy in ... accreditation is awarded in recognition of the pharmacy,s ... --> ... --> ...
(Date:10/12/2015)... Calif. , Oct. 12, 2015 /PRNewswire/ ... and Chief Scientific Officer of Asterias Biotherapeutics, ... company in the emerging field of regenerative ... webcast, sponsored in part by Asterias Biotherapeutics, ... Lebkowski will discuss the progress to date ...
(Date:10/12/2015)... , Oct. 12, 2015  In a Sutter ... the Journal of Neurology, Neurosurgery, and Psychiatry, the blood ... brain atrophy and cognitive decline in patients in the ... --> --> IVIG, extracted from the ... to amyloid, an abnormal brain protein found in patients ...
Breaking Medicine Technology:
(Date:10/12/2015)... , ... October 12, 2015 , ... ... teams up with the Cleveland Clinic in honor of Breast Cancer Awareness Month. ... Sunset Pink color, AcousticSheep will donate a SleepPhones® Classic product to a breast ...
(Date:10/12/2015)... ... October 12, 2015 , ... Advera Health Analytics, Inc ... to qualified Managed Care Organizations (MCOs) in order to provide health plans, payers, systems, ... decision making process. In addition, the DSM is also being offered to healthcare media ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... On July ... MN. Their mission: To paddle the entire 2,320-miles of river to the Gulf of ... halfway done with the monumental journey, with two months remaining for a November 22nd ...
(Date:10/12/2015)... PA (PRWEB) , ... October 12, 2015 , ... A ... are labeled as “child safe.” An inventor from Rutland, Mass., has modified a conventional ... V NOSE SUCKER to use in withdrawing mucus from sinuses and nasal passages more ...
(Date:10/12/2015)... Clara, CA (PRWEB) , ... October 12, 2015 , ... Santa Clara dentist , ... hygiene with the information provided by the ADHA white paper announcement. , “I want each ... them to have the best possible smile,” states Santa Clara dental implants dentist , ...
Breaking Medicine News(10 mins):